生存率

如果能在病情造成严重损害前及早发现血色病并加以治疗,患者通常可以享受充实生活。但如果不予治疗,尤其是在导致晚期肝脏瘢痕形成(肝硬化)或心脏状况后,生存期可能显著缩短。

许多因素会影响该状况的进展(也称为预后)。

  • 出生指定性别。 男性通常更早出现症状,并发症也更严重。
  • 确诊时的年龄。 在 56 岁或以上时确诊,预后通常较差。
  • 体内铁水平。 如果在确诊时您的血清铁蛋白水平低于 2000 微克/升,则您的生存期可能接近一般人群。
  • 确诊时间的早晚。 如果在肝硬化或糖尿病出现之前开始接受放血治疗,您通常可以过上充实的生活。
  • 如果您患有肝硬化。 如果您患有肝硬化,尤其是晚期肝硬化,预后通常较差且生存期会缩短。
  • 遗传性 HFE 基因突变。 如果您的血色病是由 HFE 基因引起,会有更高风险死于肝细胞癌(一种肝癌)。已患有肝硬化者发生这类癌症的风险最高。
  • 饮酒。 饮酒会增加血色病患者的死亡风险。酒精可能提高血液中的铁水平。

放血疗法本身可以提高生存率,哪怕您已经出现器官损伤。而且通过治疗,某些器官损伤可以在体内铁质得到清除后逆转。肝硬化通常无法逆转,但肝脏瘢痕可能有所改善。此外,治疗可以减缓或逆转其他并发症,例如糖尿病和其他肝病。

May 14, 2026
  1. Feldman M, et al., eds. Hemochromatosis. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 11th ed. Elsevier; 2021. https://www.clinicalkey.com. Accessed Sept. 23, 2024.
  2. Ferri FF. Hemochromatosis. In: Ferri's Clinical Advisor 2026. Elsevier; 2026. https://www.clinicalkey.com. Accessed Oct. 9, 2025.
  3. Hereditary hemochromatosis. American College of Gastroenterology. https://gi.org/topics/hereditary-hemochromatosis-hh/. Accessed Oct. 9, 2025.
  4. Hemochromatosis. American Liver Foundation. https://liverfoundation.org/liver-diseases/rare-disease/hemochromatosis/. Accessed Oct. 9, 2025.
  5. Kellerman RD, et al. Hemochromatosis. In: Conn's Current Therapy 2024. Elsevier; 2024. https://www.clinicalkey.com. Accessed Sept. 23, 2024.
  6. Romon I, et al. Adverse effects of therapeutic phlebotomies: Prospective study of 587 procedures. Transfusion. 2024; doi:10.1111/trf.17862.
  7. Palmer WC, et al. In the clinic: Hemochromatosis. Annals of Internal Medicine. 2025; doi:10.7326/ANNALS-24-03710.
  8. Girelli D, et al. Diagnosis and management of hereditary hemochromatosis: Lifestyle modification, phlebotomy, and blood donation. Hematology, the ASH Education Program. 2024; doi:10.1182/hematology.2024000568.
  9. Phatak P, et al. Clinical manifestations and diagnosis of hereditary hemochromatosis. https://www.uptodate.com/contents/search. Accessed Oct. 1, 2025.
  10. Kwiatkowski JL. Approach to the patient with suspected iron overload. https://www.uptodate.com/contents/search. Accessed Oct. 13, 2025.
  11. Hemosiderosis. Merck Manual Professional Version. https://www.merckmanuals.com/professional/hematology-and-oncology/iron-overload/hemosiderosis. Accessed Oct. 13, 2025.
  12. Goldman L, et al., eds. Iron overload (hemochromatosis). In: Goldman-Cecil Medicine. 27th ed. Elsevier; 2024. https://www.clinicalkey.com. Accessed Oct. 20, 2025.
  13. Adam MP, et al., eds. HFE-related hemochromatosis. In: GeneReviews. University of Washington, Seattle; 1993-2025. https://www.ncbi.nlm.nih.gov/books/NBK1116. Accessed Oct. 1, 2025.
  14. Hereditary hemochromatosis algorithm. Mayo Clinic Laboratories. https://www.mayocliniclabs.com/-/media/it-mmfiles/Special-Instructions/9/A/8/Hereditary_Hemochromatosis_Algorithm.pdf. Accessed Oct. 1, 2025.
  15. Ferritin, serum. Mayo Clinic Laboratories. https://www.mayocliniclabs.com/test-catalog/overview/619953#clinical-and-interpretive. Accessed Oct. 1, 2025.
  16. Adams P, et al. Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype. Hepatology International. 2018; doi:10.1007/s12072-018-9855-0.
  17. Phatak P, et al. Management and prognosis of hereditary hemochromatosis. https://www.uptodate.com/contents/search. Accessed Oct. 22, 2025.

相关

相关医疗程序

产品与服务